Apogee Therapeutics (APGE) Net Income towards Common Stockholders (2022 - 2026)
Apogee Therapeutics (APGE) posted quarterly Net Income towards Common Stockholders of -$74.1 million for Q1 2026, down 33.92% year-over-year from -$112.2 million in Q1 2025, and down 6.81% quarter-over-quarter from -$69.4 million in Q4 2025.
Apogee Therapeutics (APGE) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Net Income towards Common Stockholders for 5 consecutive years, with -$74.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 33.92% year-over-year to -$74.1 million; the TTM figure through Mar 2026 stood at -$274.6 million (down 33.7% YoY), while the FY2025 annual figure was -$255.8 million, down 40.46% from the prior year.
- Net Income towards Common Stockholders eased to -$74.1 million in Q1 2026 per APGE's latest filing, from -$69.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$1.8 million in Q2 2022 and bottomed at -$74.1 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$39.5 million across 5 years, with a median of -$33.0 million in 2024.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders plunged 939.92% — and 2025, when it decreased 3.23%.
- Apogee Therapeutics' Net Income towards Common Stockholders stood at -$14.0 million in 2022, then slumped by 126.57% to -$31.7 million in 2023, then tumbled by 111.81% to -$67.2 million in 2024, then slipped by 3.23% to -$69.4 million in 2025, then retreated by 6.81% to -$74.1 million in 2026.
- Business Quant data shows APGE's Net Income towards Common Stockholders at -$74.1 million in Q1 2026, -$69.4 million in Q4 2025, and -$65.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | -85.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -85.85 Mn |
| Mar 31, 2026 | -74.11 Mn |
| Dec 31, 2025 | -69.39 Mn |
| Sep 30, 2025 | -65.02 Mn |
| Jun 30, 2025 | -66.10 Mn |
| Mar 31, 2025 | -55.34 Mn |
| Dec 31, 2024 | -67.22 Mn |
| Sep 30, 2024 | -49.02 Mn |
| Jun 30, 2024 | -33.82 Mn |
| Mar 31, 2024 | -32.09 Mn |
| Dec 31, 2023 | -31.74 Mn |
| Sep 30, 2023 | -20.84 Mn |
| Jun 30, 2023 | -18.89 Mn |
| Mar 31, 2023 | -12.53 Mn |
| Dec 31, 2022 | -14.01 Mn |
| Sep 30, 2022 | -19.66 Mn |
| Jun 30, 2022 | -1.82 Mn |